Skip to main content

Kintz Samuel's Form 4 filing

Enliven Therapeutics, Inc.ELVN · filed Aug 20, 2025

Accession no.
0001415889-25-022459
Filed
Aug 20, 2025
Trade date
Aug 18-19, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $219.9K. It was filed 2 days after the trade.

This filing was later replaced by the amendment 0001415889-25-022649 (Aug 21, 2025). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kintz SamuelCIK 0001967168Director, Officer (PRESIDENT AND CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 18, 2025Common StockSSaleDisposed−10,393$20.02F2−$208,067.86929,999Indirect
Aug 19, 2025Common StockSSaleDisposed−590$20.00−$11,800929,409Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $19.75 to $20.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)